Q linea

Q linea OCF Margin

The Operating Cash Flow Margin of Q linea (QLINEA.ST) as of Oct 15, 2026 is -1,460.79 %. In the previous year, Operating Cash Flow Margin was -7,726.29 % — a change of -81.09% (higher).

OCF Margin

-1,460.79 %

YoY

-81.09%

Last updated:

Operating Cash Flow Margin of Q linea is 2025 -1,460.79 % . Operating Cash Flow Margin of Q linea was 2024 -7,726.29 % . It decreases by -81.09% higher compared to the previous year.

The Q linea OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-11,511.44 SEK
Jan 1, 2019
-16,891.54 SEK
Jan 1, 2020
-97,656.38 SEK
Jan 1, 2021
-2,732.19 SEK
Jan 1, 2022
-1,961.71 SEK
Jan 1, 2023
-5,146.87 SEK
Jan 1, 2024
-7,726.29 SEK
Jan 1, 2025
-1,460.79 SEK
The Q linea OCF Margin history
YEAROCF MarginYoY
-1,460.79 %-81.09%
-7,726.29 %+50.12%
-5,146.87 %+162.37%
-1,961.71 %-28.20%
-2,732.19 %-97.20%
-97,656.38 %+478.14%
-16,891.54 %+46.74%
-11,511.44 %+174.67%
-4,191.00 %-93.57%
-65,227.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q linea AB, listed on the Stockholm Stock Exchange under the ticker QLINEA.ST, is a health care company headquartered in Uppsala, Sweden. The company, which went public on December 7, 2018, employs 122 full-time staff. Q linea AB operates as a holding company focused on the development and manufacturing of in-vitro diagnostic (IVD) solutions for infectious diseases. Its primary product candidate, ASTar, is a fully automated instrument designed for Antibiotic Susceptibility Testing (AST). The system utilizes proprietary disposables to measure bacterial antimicrobial susceptibility, providing a susceptibility profile within three to six hours directly from a positive blood culture. This rapid testing capability allows for early targeted antibiotic administration, specifically addressing the pathogen causing the infection. The company's main application targets sepsis identification in hospital patients, with its products primarily intended for use in hospital laboratories. Q linea AB's technology aims to improve diagnostic speed and precision in clinical settings, particularly for critical conditions requiring prompt treatment. The company's website is www.qlinea.com, where further information about its products and services can be found. As a publicly traded entity, Q linea AB is subject to standard financial reporting requirements for listed companies in Sweden. The company's focus on infectious disease diagnostics positions it within a specialized segment of the health care industry. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

Operating Cash Flow Margin of Q linea is -1,460.79 % in 2025.

Operating Cash Flow Margin of Q linea changed from -7,726.29 % to -1,460.79 %, representing a -81.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Q linea since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Q linea with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Q linea

All Key Metrics — Q linea